# EDGAR Filing Document

**Accession Number:** 0001818838
**File Stem:** 0001104659-26-030000
**Filing Date:** 2026-3
**Character Count:** 8207
**Document Hash:** b6ea168a91db3740f69fe6a892e2798c
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-26-030000.hdr.sgml**: 20260318

**ACCESSION NUMBER**: 0001104659-26-030000

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260318

**FILED AS OF DATE**: 20260318

**DATE AS OF CHANGE**: 20260318

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** GU CHUNFANG
- **CENTRAL INDEX KEY:** 0002108105

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39997
- **FILM NUMBER:** 26765962

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 4F, BUILDING C14, NO. 218 XINGHU STREET
- **CITY:** SUZHOU
- **NON US STATE TERRITORY:** JIANGSU
- **PROVINCE COUNTRY:** F4
- **ZIP:** 215123
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Adagene Inc.
- **CENTRAL INDEX KEY:** 0001818838
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 4F, BUILDING C14, NO. 218, XINGHU STREET
- **STREET 2:** SUZHOU INDUSTRIAL PARK
- **CITY:** JIANGSU
- **STATE:** F4
- **ZIP:** 00000
- **BUSINESS PHONE:** 86-512-87773632

**MAIL ADDRESS:**
- **STREET 1:** 4F, BUILDING C14, NO. 218, XINGHU STREET
- **STREET 2:** SUZHOU INDUSTRIAL PARK
- **CITY:** JIANGSU
- **STATE:** F4
- **ZIP:** 00000

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>GU CHUNFANG<br><sub>(Last) (First) (Middle)</sub><br>4F, BUILDING C14, NO. 218 XINGHU STREET<br><sub>(Street)</sub><br>SUZHOU JIANGSU, CHINA 215123<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>Adagene Inc. [ ADAG ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2026-03-18 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director   [ ] 10% Owner<br>[X] Officer (give title below)   [ ] Other (specify below)<br>_Executive Director of Finance_ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |
| Ordinary Shares | 7045 | D |  |
| Restricted Stock Unit | 23438<sup>(1)</sup> | D |  |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| Incentive Stock Option (Right to Buy) | <sup>(2)</sup> | 2029-02-28 | Ordinary Shares | 30000 | $1.33 | D |  |
| Nonqualified Stock Option (Right to Buy) | <sup>(3)</sup> | 2030-03-26 | Ordinary Shares | 30000 | $1.48 | D |  |
| Nonqualified Stock Option (Right to Buy) | <sup>(4)</sup> | 2030-08-15 | Ordinary Shares | 20000 | $1.83 | D |  |
| Nonqualified Stock Option (Right to Buy) | <sup>(5)</sup> | 2032-02-07 | Ordinary Shares | 1250 | $5.60 | D |  |
| Nonqualified Stock Option (Right to Buy) | <sup>(6)</sup> | 2033-05-03 | Ordinary Shares | 20000 | $1.04 | D |  |
| Nonqualified Stock Option (Right to Buy) | <sup>(7)</sup> | 2033-12-27 | Ordinary Shares | 20000 | $1.33 | D |  |
| Nonqualified Stock Option (Right to Buy) | <sup>(8)</sup> | 2034-11-17 | Ordinary Shares | 19869 | $1.73 | D |  |
| Nonqualified Stock Option (Right to Buy) | <sup>(9)</sup> | 2034-12-24 | Ordinary Shares | 30000 | $1.55 | D |  |
| Nonqualified Stock Option (Right to Buy) | <sup>(10)</sup> | 2035-06-05 | Ordinary Shares | 55000 | $1.408 | D |  |
| Nonqualified Stock Option (Right to Buy) | <sup>(11)</sup> | 2036-02-05 | Ordinary Shares | 40000 | $2.032 | D |  |

---

### Footnotes:

(1) 23,438 of Restricted Stock Units ("RSUs") granted under the Adagene Inc. 2021 Performance Incentive Plan. 7,813 of RSUs shall vest on each of the following dates: 7/23/2026, 7/23/2027, and 7/23/2028.

(2) 30,000 of time-based incentive stock option granted under the Adagene Inc. Second Amended and Restated Share Incentive Plan (pre-IPO), and all such option are fully vested and exercisable.

(3) 30,000 of time-based incentive stock option granted under the Adagene Inc. Second Amended and Restated Share Incentive Plan (pre-IPO), and all such option are fully vested and exercisable.

(4) 20,000 of performance-based incentive stock options granted under the Adagene Inc. Second Amended and Restated Share Incentive Plan (pre-IPO), and all such option are fully vested and exercisable.

(5) 1,250 of performance-based stock options granted under the Adagene Inc. 2021 Performance Incentive Plan, and all such option are fully vested and exercisable.

(6) 20,000 of time-based stock option granted on 5/3/2023 under the Adagene Inc. 2021 Performance Incentive Plan. The options shall become exercisable with respect to 25% of the options on each of the first four anniversaries of the grant date. Accordingly, 10,000 shares subject to this option are vested and exercisable.

(7) 20,000 of time-based stock option granted on 12/27/2023 under the Adagene Inc. 2021 Performance Incentive Plan. The options shall become exercisable with respect to 25% of the options on each of the first four anniversaries of the grant date. Accordingly, 10,000 shares subject to this option are vested and exercisable.

(8) 19,869 of time-based stock option granted on 11/17/2024 under the Adagene Inc. 2021 Performance Incentive Plan. 50% of the options shall vest on 6/30/2025 and 6/30/2026, respectively, accordingly, 9,935 shares subject to this option are vested and exercisable.

(9) 30,000 of time-based stock option granted on 12/24/2024 under the Adagene Inc. 2021 Performance Incentive Plan. The options shall become exercisable with respect to 25% of the options on each of the first four anniversaries of the grant date. Accordingly, 7,500 shares subject to this option are vested and exercisable.

(10) 55,000 of time-based stock option granted on 6/5/2025 under the Adagene Inc. 2021 Performance Incentive Plan. The options become exercisable with respect to 25% of the shares on each of the first four anniversaries of the grant date.

(11) 40,000 of time-based stock option granted on 2/5/2026 under the Adagene Inc. 2021 Performance Incentive Plan. The options become exercisable with respect to 25% of the shares on each of the first four anniversaries of the grant date.

**Signature:** /s/ Chunfang GU  
**Date:** 2026-03-18

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**